Status:
COMPLETED
Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria
Lead Sponsor:
Medical University of Graz
Collaborating Sponsors:
AGES
Medical University Innsbruck
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
The coronavirus disease 2019 (COVID-19) pandemic was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. In this study, we aim to evaluate how strong and how long are ind...
Eligibility Criteria
Inclusion
- \- Residency in Austria.
Exclusion
- \- None.
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
9090868 Patients enrolled
Trial Details
Trial ID
NCT06162533
Start Date
July 1 2023
End Date
July 1 2023
Last Update
December 8 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Austria, 8036
2
Medical University of Innsbruck
Innsbruck, Austria
3
Austrian Agency for Health and Food Safety
Vienna, Austria